Uncompromising Commitment to Research
Our unique global partnering philosophy emphasizes an uncompromising commitment to clinical research and to the highest level of ethical standards and performance in our jobs. We are selective about the projects we engage in because we are devoted to quality and providing our partners with best-in-class service.
Medpace’s dedicated teams serve as an extension of your team – we engage quickly and provide strategic thinking – ensuring quicker start-up times, superior quality, and the most efficient delivery of every phase of your clinical trial. Our therapeutic and regulatory experts are committed to streamlining your path to approval so every partnership is designed to create research solutions focused on your critical needs.
Making the Complex Seamless
Operating under a full-service model, Medpace provides a therapeutically focused, integrated, global, and quality partner for seamless execution.
A Full-Service CRO
Long-standing relationships with sponsors demonstrates how our full-service outsourcing model delivers higher quality results.
Why Sponsors Choose Medpace
We asked our Sponsors why they chose Medpace as their clinical development partner. Here is what they said:
“We are always pleasantly surprised with how the Medpace team reciprocates with nonchalance to the impossible deadlines we set for ourselves to speed up drug development to get our investigational agents to market authorization. For example, with just a two-day turnaround from data cut, Medpace produced the SDTM output despite some last minute, unexpected hiccups. The work put into supporting our goal by Medpace’s study team, monitoring team and data management team to orchestra patient visits, monitoring visits and data cleaning effort over a 20 day period needs special mention. This is a testament to a great partnership and to the wonderful people we get to work with on a daily basis. We look forward to collaborating further for the betterment of patient lives around the world.”
Senior Manager, Clinical Operations, Biopharmaceutical Company